Predictors of Response and Survival in Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular Carcinoma

Immune checkpoint inhibitors (ICIs) with nivolumab and pembrolizumab are promising agents for advanced hepatocellular carcinoma (HCC) but lack of effective biomarkers. We aimed to investigate the potential predictors of response and factors associated with overall survival (OS) for ICI treatment in...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Pei-Chang, Chao, Yee, Chen, Ming-Huang, Lan, Keng-Hsin, Lee, Chieh-Ju, Lee, I-Cheng, Chen, San-Chi, Hou, Ming-Chih, Huang, Yi-Hsiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017111/
https://www.ncbi.nlm.nih.gov/pubmed/31940757
http://dx.doi.org/10.3390/cancers12010182

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017111/
https://www.ncbi.nlm.nih.gov/pubmed/31940757
http://dx.doi.org/10.3390/cancers12010182

Ejemplares similares